The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 27, 2015
Filed:
Dec. 08, 2011
Applicants:
Alexander R. Hurd, Ann Arbor, MI (US);
Clarke B. Taylor, Ann Arbor, MI (US);
Peter L. Toogood, Ann Arbor, MI (US);
Chad A. Van Huis, Hartland, MI (US);
Inventors:
Alexander R. Hurd, Ann Arbor, MI (US);
Clarke B. Taylor, Ann Arbor, MI (US);
Peter L. Toogood, Ann Arbor, MI (US);
Chad A. Van Huis, Hartland, MI (US);
Assignee:
Lycera Corporation, Ann Arbor, MI (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 279/22 (2006.01); C07C 309/04 (2006.01); C07C 311/07 (2006.01); C07C 317/44 (2006.01); C07D 239/28 (2006.01); C07D 213/81 (2006.01); C07D 333/38 (2006.01); C07D 295/195 (2006.01); C07D 213/74 (2006.01); C07D 239/32 (2006.01); C07D 241/04 (2006.01); C07D 203/22 (2006.01); C07D 207/34 (2006.01); C07D 211/58 (2006.01); C07D 295/205 (2006.01); C07D 295/30 (2006.01); C07D 213/38 (2006.01); C07D 307/22 (2006.01); C07D 307/66 (2006.01);
U.S. Cl.
CPC ...
C07C 279/22 (2013.01); C07C 309/04 (2013.01); C07C 311/07 (2013.01); C07C 317/44 (2013.01); C07D 203/22 (2013.01); C07D 207/34 (2013.01); C07D 211/58 (2013.01); C07D 213/38 (2013.01); C07D 213/74 (2013.01); C07D 213/81 (2013.01); C07D 239/28 (2013.01); C07D 239/32 (2013.01); C07D 241/04 (2013.01); C07D 295/195 (2013.01); C07D 295/205 (2013.01); C07D 295/30 (2013.01); C07D 307/22 (2013.01); C07D 307/66 (2013.01); C07D 333/38 (2013.01); C07B 2200/07 (2013.01); C07C 2101/02 (2013.01); C07C 2101/08 (2013.01); C07C 2101/14 (2013.01);
Abstract
The invention provides cycloalkyl guanidine compounds that inhibit FF-ATPase, and methods of using cyclalkyl guanidine compounds as therapeutic agents in therapy, such as treating an immune disorder, inflammatory condition, or cancer.